Liminatus Pharma Corp - LIMN Net earnings per share for the last four quarters

Official company branding of Liminatus Pharma Corp (LIMN)

Liminatus Pharma is implementing ESG standards in the development of antitumor agents, reducing laboratory emissions and adhering to testing ethics. The business relies on CAR-T innovations for personalized therapy for gastrointestinal cancers. The confirmed price history on the chart reflects EPS (TTM) dynamics at -106.80. The company is currently implementing robotic molecule screening and software automation for clinical data analysis to accelerate drug release.

Liminatus Pharma LLC (LIMN) Earnings per share for the last twelve months: for the period 11/23/2025 - 11/18/2026

LIMN (Liminatus Pharma LLC): analytical breakdowns and indicator data

Initial company analysis:LIMN, Liminatus Pharma Corp
Mass-produced product of liminatuspharma.com

This indicator measures the dynamics of net earnings per share on a rolling year basis, allowing investors to assess business scaling rates and capital management efficiency. When analyzing YoY EPS changes on a rolling 12-month basis via the GURU.Markets platform, profitability peaks should be correlated with the full operational readiness of production capacities and the loading schedule of Liminatus Pharma (LIMN) oncology laboratories.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months